Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 15/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715382 | 1.00 | ALDH1A1 (0.49) | ALDH1A1TSHRPDE5APDE4APDE4B | |
| SCHEMBL16626181 | 1.00 | ALDH1A1 (0.49) | ALDH1A1TSHRPDE5APDE4APDE4B | |
| SCHEMBL8799430 | 0.85 | ALDH1A1 (0.49) | ALDH1A1TSHRPDE5APDE4APDE4B | |
| SCHEMBL715169 | 0.85 | ALDH1A1 (0.49) | ALDH1A1TSHRPDE5APDE4APDE4B | |
| SCHEMBL715170 | 0.85 | ALDH1A1 (0.49) | ALDH1A1TSHRPDE5APDE4APDE4B | |
| SCHEMBL7440439 | 0.81 | PDE5A (0.67) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL237742 | 0.81 | PDE5A (0.64) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL193091 | 0.81 | PDE5A (0.67) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL193092 | 0.81 | PDE5A (0.67) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL237741 | 0.81 | PDE5A (0.64) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10238660-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180280396-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20160375028-A1 | ORGANIC COMPOUNDS | FIENBERG ALLEN A (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-9006258-B2 | Method of treating female sexual dysfunction with a PDE1 inhibitor | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280396-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | ALDH1A1 22/4885TSHR 3127/4885PDE5A 1/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | ALDH1A1 1873/4885TSHR 3757/4885PDE5A 1/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | ALDH1A1 1254/4885TSHR 3845/4885PDE5A 1/4885 |
| US-10010553-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | ALDH1A1 22/4885TSHR 3127/4885PDE5A 1/4885 |
| US-20160375028-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | ALDH1A1 22/4885TSHR 3127/4885PDE5A 1/4885 |
| US-10238660-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | ALDH1A1 22/4885TSHR 3127/4885PDE5A 1/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | ALDH1A1 1873/4885TSHR 3757/4885PDE5A 1/4885 |
| US-11166956-B2 | Combinations of PDE1 inhibitors and NEP inhibitors | PDE5A, ECE1, PDE3A | ALDH1A1 1336/4885TSHR 3893/4885PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.